home / stock / otic / otic news

OTIC News and Press, Otonomy Inc. From 03/12/19

Stock Information
Company Name: Otonomy Inc.
Stock Symbol: OTIC
Market: OTC
Website: otonomy.com
Menu
OTIC OTIC Quote OTIC Short OTIC News OTIC Articles OTIC Message Board
Get OTIC Alerts

News, Short Squeeze, Breakout and More Instantly...
OTIC - Otonomy (OTIC) Presents At Cowen And Company 39th Annual Health Care Conference - Slideshow

The following slide deck was published by Otonomy, Inc. in conjunction with this Read more ...

OTIC - Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to participat...

OTIC - Otonomy (OTIC) CEO David Weber on Q4 2018 Results - Earnings Call Transcript

Otonomy (OTIC) Q4 2018 Earnings Conference Call March 4, 2019 04:30 PM ET Company Participants Robert H. Uhl - Westwicke Partners David Weber - President, CEO Paul E. Cayer - Chief Financial & Business Officer Conference Call Participants Stacy Ku - Cowen and Company ...

OTIC - GME, NVTA, PS and SOI among after hours movers

Gainers: OTIC   +5.5% . DERM   +4.9% . GME   +3.9% . SOI   +3.2% . CTBB   +3.1% . More news on: Otonomy, Dermira, GameStop Corp., Stocks on the move, Read more ...

OTIC - Otonomy beats by $0.06, beats on revenue

Otonomy (NASDAQ: OTIC ): Q4 GAAP EPS of -$0.42 beats by $0.06 . More news on: Otonomy, Earnings news and commentary, Healthcare stocks news, , Read more ...

OTIC - Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

OTIVIDEX™  Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019 OTO-413 Phase 1/2 trial in hearing loss expected to start in third ...

OTIC - Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2018 as well as provide ...
OTIC - Analysis: Positioning to Benefit within Apache, A. O. Smith, Diamondback Energy, Maiden, Lands' End, and Otonomy - Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Apache Corporation (NYSE:APA), A. O. Smith Corporation (NYSE:AOS), Dia...

OTIC - Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 42nd A...

OTIC - Here Is Otonomy

If you are of the fallen angel school of biotech investing, Otonomy ( OTIC ) is worth a listen. If you are wary of falling knives, not so much. Although some may see it as an interesting speculation, I am taking a pass on this one for the time being. I set out my thinking below. Back in 2017...
Previous 10 Next 10